In a small study, recurrent Clostridioides difficile infection (CDI) therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.
The live biotherapeutic product, fecal microbiota, notably live-jslm (Rebyota) was
Since its approval, there have been a number of studies looking at its efficacy and durability over time.
A new study published in Open Forum Infectious Diseases demonstrated long-term protection of Rebyota in a patient population that was exposed to non-CDI antibiotic use.1
“Across all evaluable time points, 86% (37/43) of participants had treatment response regardless of when non-CDI antibiotic exposure occurred,” the investigators wrote.1
“RBL[ Rebyota] remained efficacious in participants with a history of rCDI after subsequent non-CDI antibiotic exposure,” the investigators wrote.
Learn more:
Rebyota demonstrated long-term protection in patients exposed to non-CDI antibiotics. Across all time points, 86% of participants had a treatment response, regardless of when non-CDI antibiotic exposure occurred.
Treatment response was sustained for a median duration of 470 days from the first day of initial non-CDI antibiotic use.
Rebyota may restore the gut microbiota to a sufficient threshold protective against recurrent CDI, even after subsequent non-CDI antibiotic use
Study Parameters and Takeaways
Investigators wanted to looking at the durability of the Rebyota in patients who were using non-CDI antibiotics. This subgroup was looked at up to 2 years after administration of the C diff therapy.
“Treatment response was sustained for a median duration of 470 days [interquartile range: 212–648] from the first day of initial non-CDI antibiotic use,” the investigators wrote. “Most participants (5/6) with CDI recurrences received a high-risk antibiotic.”
“These results suggest RBL [Rebyota] may restore the gut microbiota to a sufficient threshold protective against rCDI for many patients despite subsequent non-CDI antibiotic use," the authors wrote.
C diff is estimated to infect approximately 500,000 patients annually in the US, and of these around 30,000 will die.2
Recurrent C diff infection is associated with even higher rates of morbidity and mortality, treatment options are limited or may worsen the problem by further disrupting the gut microbiome.
